Evidence map›Paper›PMID 38647931›Full record

ArticleBioresources and bioprocessing2024

Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins.

Douglas Nolan, Thomas R Chin, Mick Eamsureya, Sheldon Oppenheim, Olga Paley, Christina Alves, George Parks

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioresources and bioprocessing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Douglas NolanTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA. Douglas.Nolan@takeda.com.ORCID http://orcid.org/0000-0003-1420-8518
Thomas R ChinTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.ORCID http://orcid.org/0009-0002-8388-2610
Mick EamsureyaEurofins Lancaster Laboratories Professional Scientific Services, LLC, Lancaster, PA, 17601, USA.
Sheldon OppenheimTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.
Olga PaleyTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.
Christina AlvesTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.
George ParksTakeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) require a high level of purity for regulatory approval and safe administration. High-molecular weight (HMW) species are a common impurity associated with mAb therapies. Hydrophobic interaction chromatography (HIC) resins are often used to remove these HMW impurities. Determination of a suitable HIC resin can be a time and resource-intensive process. In this study, we modeled the chromatographic behavior of seven mAbs across 13 HIC resins using measurements of surface hydrophobicity, surface charge, and thermal stability for mAbs, and hydrophobicity and zeta-potential for HIC resins with high fit quality (adjusted R

Indexed as

BioengineeringBioprocess engineeringChromatographyStatistical analysis

Identifiers

PMID38647931
PMCPMC10991917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.